Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
micrococcus luteus Q24 lysate ointment
- Development stage
- Discontinued
- Lead developer
- BLIS Technologies
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
Micrococcus luteus Q24 lysate ointment is a topical biologic formulation developed by the University of Otago in collaboration with Blis Technologies. The active ingredient is a lysate (killed-cell preparation) of *Micrococcus luteus* strain Q24 (BLIS Q24™), a human skin commensal bacterium. Formulated at a 5% concentration in a Cetomacrogol ointment base, the drug targets the skin microbiome to inhibit pathogenic bacteria associated with inflammatory skin conditions, including *Staphylococcus aureus* and *Cutibacterium acnes*. It was investigated as a treatment for eczema (atopic dermatitis) in a Phase 1 safety study in New Zealand adults, which was terminated early.
- Brand names
- BLIS Q24™
- Other names
- Micrococcus luteus strain Q24 lysate ointmentBLIS Q24 lysate ointment
Beyond the preview
Go deeper on micrococcus luteus Q24 lysate ointment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on micrococcus luteus Q24 lysate ointment.